Navigating UnitedHealthcare Ocrevus Prior Authorization

Understanding Ocrevus and UnitedHealthcare Coverage Dynamics

Ocrevus (ocrelizumab) is a high-volume specialty drug primarily indicated for relapsing or primary progressive forms of multiple sclerosis (MS). As a significant investment in patient care, Ocrevus requires prior authorization across UnitedHealthcare's diverse plans, including commercial, Medicare Advantage, and Medicaid managed care. Navigating UnitedHealthcare's specific medical necessity criteria for this therapy is paramount for successful authorization.

UnitedHealthcare Prior Authorization Channels for Specialty Drugs

UnitedHealthcare directs medical-benefit prior authorizations through its UHCprovider.com portal, which accepts procedure-specific PA initiation and document uploads. For pharmacy benefit Ocrevus, submissions route through OptumRx, UnitedHealth Group's PBM, which also manages many specialty injectables and infusions. X12 278 transactions are supported via clearinghouses for medical benefit procedures, and OptumRx leverages ePA partners like CoverMyMeds and Surescripts for prescriber-initiated pharmacy benefit workflows.

Key Considerations for Ocrevus PA Submission to UnitedHealthcare

• **Medical Necessity Criteria:** Consult the UnitedHealthcare Medical Policy Library for current coverage rules and clinical criteria for Ocrevus.
• **Specialty Pharmacy Program:** Verify if Ocrevus falls under OptumRx's Specialty Pharmacy Drug Program, which dictates submission pathways and potential site-of-care policies.
• **Documentation Requirements:** Ensure all clinical notes, diagnostic test results, and treatment history align with UHC's specific policy requirements for MS therapies.
• **Benefit Verification:** Confirm whether Ocrevus is covered under the medical or pharmacy benefit, as this influences the correct submission channel.
• **Site-of-Care Policies:** Be aware of any UHC policies that may require infusion at specific sites, such as home or freestanding centers, over hospital outpatient settings.

Navigating UnitedHealthcare's UM Policies and Turnaround Times

UnitedHealthcare publishes medical-necessity criteria and coverage rules through its public Medical Policy Library. Turnaround times for Ocrevus prior authorizations are influenced by state-mandated minimums, UHC's published service-level targets, and NCQA Utilization Management accreditation standards. For UnitedHealthcare's Medicare Advantage, Community Plan (Medicaid), CHIP, and QHP-on-FFM lines, CMS-0057-F mandates 72-hour standard and 24-hour expedited PA decisions, with phased compliance timelines for electronic PA API conformance by 2027. UHC's commercial book is not directly impacted by CMS-0057-F.

Common Denial Reasons and Effective Appeals for Ocrevus with UHC

Denials for Ocrevus prior authorizations from UnitedHealthcare often stem from categories such as medical necessity, insufficient clinical documentation, failure to meet step therapy requirements, or site-of-service mismatches. For a denied Ocrevus authorization, UnitedHealthcare documents appeal pathways in its provider administrative guides, which differ by line of business. Peer-to-peer reviews are available for clinical denials, providing an avenue for prescribers to discuss the medical necessity directly with a UHC medical reviewer.

Klivira's Role in Streamlining UnitedHealthcare Ocrevus Prior Authorizations

Klivira's prior authorization automation platform integrates with EMRs and payer portals, including UHCprovider.com and OptumRx, to streamline the complex process for specialty drugs like Ocrevus. By automating data extraction, submission via X12 278 or portal, and status tracking, Klivira helps reduce manual effort, minimize errors, and accelerate decision times. This enables clinics, hospitals, and health systems to improve patient access to critical MS treatments while optimizing revenue cycle performance.